Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year updateThomas H. Brannagan, Michael Polydefkis, P. James B. Dyck et al.|Journal of Neurology|2022Cited by 36
Efficacy and safety with >3 years of inotersen treatment for the polyneuropathy of hereditary transthyretin amyloidosisTeresa Coelho, Morie A. Gertz, Carol Whelan et al.|Journal of the Neurological Sciences|2021Cited by 0